Naltrexone but not ketanserin antagonizes the subjective, cardiovascular and neuroendocrine effects of salvinorin-A in humans

Salvinorin-A and opioid antagonism

Ana Elda Maqueda MSc, Marta Valle PhD, Peter H. Addy PhD, Rosa Maria Antonijojan PhD, Montserrat Puntes MD, Jimena Coimbra MD, Maria Rosa Ballester MSc, Maite Garrido MSc, Mireia González MSc, Judit Claramunt MSc, Steven Barker PhD, Izabela Lomnicka PhD, Marian Waguespack PhD, Matthew W. Johnson PhD, Roland R. Griffiths PhD and Jordi Riba PhD

1Human Neuropsychopharmacology Group. Sant Pau Institute of Biomedical Research (IIB-Sant Pau). Sant Antoni Maria Claret, 167, 08025, Barcelona, Spain.
2Centre d’Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
3Departament de Farmacologia i Terapèutica, Universitat Autònoma de Barcelona.
4Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM.
6Medical Informatics, VA Connecticut Healthcare System, West Haven, CT 06516, USA
7Medical Informatics, Yale University School of Medicine, New Haven, CT 06511, USA
8Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Skip Bertman Drive at River Road, Baton Rouge, LA 70803, USA.
9Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224-6823, USA
10Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21224-6823, USA.

Correspondence to:
Jordi Riba, Human Neuropsychopharmacology Group, IIB-Sant Pau.C/Sant Antoni Maria Claret, 167.08025, Barcelona, Spain.
Tel: +34 93 556 5518; Fax: +34 93 553 7864; email: jriba@santpau.cat
Abstract

Background: Salvinorin-A is a terpene found in the leaves of the plant *Salvia divinorum*. When administered to humans, salvinorin-A induces an intense but short-lasting modified state of awareness, sharing features with those induced by the classical serotonin-2A (5-HT$_{2A}$) receptor agonist psychedelics. However, unlike substances such as psilocybin or mescaline, salvinorin-A shows agonist activity at the kappa-opioid receptor (KOR) rather than at the 5-HT$_{2A}$ receptor. Here we assessed the involvement of KOR- and 5-HT$_{2A}$-agonism in the subjective, cardiovascular, and neuroendocrine effects of salvinorin-A in humans.

Methods: We conducted a placebo-controlled, randomized, double-blind study with two groups of 12 healthy volunteers with experience with psychedelic drugs. There were four experimental sessions. In Group-1 participants received the following treatment combinations: placebo+placebo, placebo+salvinorin-A, naltrexone+placebo and naltrexone+salvinorin-A. Naltrexone, a nonspecific opioid receptor antagonist, was administered at a dose of 50 mg orally. In Group-2 participants received the treatment combinations: placebo+placebo, placebo+salvinorin-A, ketanserin+placebo and ketanserin+salvinorin-A. Ketanserin, a selective 5-HT$_{2A}$ antagonist, was administered at a dose of 40 mg orally. Results: Inhalation of 1 mg of vaporized salvinorin-A led to maximum plasma concentrations at 1 and 2 minutes after dosing. When administered alone, salvinorin-A severely reduced external sensory perception and induced intense visual and auditory modifications, increased systolic blood pressure, and cortisol and prolactin release. These effects were effectively blocked by naltrexone, but not by ketanserin. Conclusions: Results support kappa opioid receptor agonism as the mechanism of action underlying the subjective and physiological effects of salvinorin-A in humans, and rule out the involvement of a 5-HT$_{2A}$-mediated mechanism.

Keywords Salvinorin-A, Naltrexone, Ketanserin, Kappa opioid receptor antagonism, Serotonin-2A antagonism, human pharmacology
Introduction

Salvinorin-A is a terpene compound thought to be the main psychoactive component present in the leaves of the plant *Salvia divinorum* (Labiatae), a mint endemic to the Sierra Madre Oriental of Oaxaca, Mexico. The plant has been used for centuries by the Mazatec people who inhabit the region in the treatment of various medical conditions and for spiritual purposes, divination, and shamanic healing (Valdés et al., 1983; Ott, J, 1995).

*S. divinorum* preparations have attracted the interest of users of psychoactive drugs worldwide, leading to widespread experimentation with the plant. The dried leaves and fortified extracts can be smoked or administered sublingually, inducing brief but intense psychotropic effects (González et al, 2006). Ortega (Ortega et al., 1982), and later Valdés (Valdes et al., 1984) isolated salvinorin-A from *S. divinorum*, which was shown to be psychoactive in a series of laboratory studies. The effects induced by the drug in humans include prominent modifications in audio-visual perception and, at higher doses, intense dissociation with disconnection from external reality and loss of contact with the body (Johnson et al., 2011; MacLean et al., 2013; Addy et al., 2015; Maqueda et al., 2015).

Salvinorin-A shows remarkable pharmacological characteristics. Although its profile of effects in humans has analogies to that of classical serotonergic psychedelics, salvinorin-A does not show affinity in vitro for the serotonin-2A (5-HT2A) receptor. Unlike drugs such as LSD, mescaline or psilocybin, salvinorin-A instead shows high affinity for the kappa opioid receptor (KOR) (Roth et al., 2002; Prisinzano, 2005). Salvinorin-A is also an unusual KOR agonist. In contrast with drugs such as pentazocine and enadoline, the salvinorin-A molecule does not contain nitrogen. Additionally, in contrast with these nitrogenated compounds, salvinorin-A displays perception-modifying rather than somato-dysphoric effects (Walsh et al., 2001), although salvinorin-A has not been compared directly with synthetic kappa agonists within one study.
Animal studies further suggest the KOR-specific profile of salvinorin-A effects. In adult rhesus monkeys, salvinorin-A induces prolactin release (Butelman et al., 2007), facial relaxation, and ptosis (Butelman et al., 2009) as well as discriminative stimulus effects (Butelman et al., 2010). All these effects are blocked by pretreatment with the KOR partial agonist nalmefene (Butelman et al., 2007, 2009) and the antagonist quadazocine (Butelman et al., 2010), but not by pretreatment with the 5-HT$_{2A}$ antagonist ketanserin (Butelman et al., 2007, 2009, 2010) or the cannabinoid antagonist rimonibant (Butelman et al., 2009). Analogous results have been obtained in mice (Walentiny et al., 2010). However, despite the evidence from in vitro assays and animal studies, to date no studies have been published demonstrating in vivo that the pharmacological effects of salvinorin-A in humans are indeed mediated by the KOR.

In the present study, we sought to investigate further the pharmacology of salvinorin-A in humans by assessing the involvement of KOR- and 5-HT$_{2A}$-agonism in the subjective, cardiovascular, and neuroendocrine effects induced by the drug. To do so we conducted a study involving salvinorin-A administration to experienced psychedelic drug users following pre-treatment with the opioid antagonist naltrexone or the 5-HT$_{2A}$ antagonist ketanserin. In addition to subjective effects measures, we utilized several outcomes known to be sensitive to KOR agonists in humans, including neuroendocrine variables such as plasma cortisol and prolactin (sensitive to salvinorin-A; Ranganathan et al., 2012), and growth hormone (sensitive to the synthetic KOR agonist spiradoline (Ur et al., 1997).
Materials and methods

Ethics

The study was conducted in accordance with the Declarations of Helsinki and its updates concerning experimentation on humans, and was approved by the hospital's ethics committee and the Spanish Ministry of Health. All participants gave their written informed consent prior to participation.

Participants

The study included 24 volunteers with previous experience in the use of psychedelics. The final participant sample had at least 10 previous experiences with psychedelics and no history of adverse effects from their use. Exclusion criteria included a current or past history of psychiatric disorders, alcohol or other substance dependence, evidence of significant illness, and pregnancy. Participants underwent a complete physical examination that included a medical history, laboratory tests, ECG, and urinalysis. Cannabis users were requested to abstain from cannabis use since enrolment and until the end of the study. This was verified by urinalysis (see below). Twelve participants were allocated to Group 1 involving the administration of naltrexone and twelve to Group 2 involving the administration of ketanserin. The first twelve participants were allocated to Group 1 (naltrexone pre-treatment group) and the subsequent twelve to Group 2 (ketanserin pre-treatment group). Additional details on the study participants is provided in the supplementary information file.

Drugs

A fully psychoactive dose of 1 mg vaporized pure (>99%) salvinorin-A was chosen for the study based on results from a previous trial (Maqueda et al, 2015). Oral capsules were prepared containing either 50 mg naltrexone, 40 mg ketanserin or lactose placebo. The chosen
naltrexone dose is the standard clinical daily dose. The ketanserin dose was chosen based on a previous study that showed that 40 mg block the subjective effects of a high dose of psilocybin (Vollenweider et al., 1998). These capsules were administered 1 hour prior to salvinorin-A vaporization and inhalation (see study design below). Additional information is provided in the supplementary file.

Study Design

The study was carried out in a double-blind randomized crossover fashion. It involved four experimental sessions one week apart. Two weeks before the beginning of the experimental sessions, volunteers were instructed to abstain from all medications (including prescription drugs) and illicit drugs, and remain drug-free throughout the study. Upon arrival in the morning to the research unit, breath analysis for alcohol, urinalysis for illicit drug use, and a urine pregnancy test (for women only) were administered. An intravenous catheter was placed in a vein of the left arm for drawing blood samples. Pretreatment capsules were administered, and one hour later, salvinorin-A or placebo was administered by vaporization and inhalation.

Participants received the following treatment combinations: oral placebo + vaporized placebo (placebo+placebo), oral placebo + vaporized salvinorin-A (placebo+salvinorin), oral study drug + vaporized placebo (naltrexone+placebo), and oral study drug + vaporized salvinorin-A (naltrexone+salvinorin). Participants received either naltrexone (Group 1) or ketanserin (Group 2) as their study drug. The order in which the different treatment combinations were administered was counterbalanced between subjects according to a randomization table. For further details on study design, see the supplementary information file.
Outcome measures

Psychological effects were captured using the Hallucinogen Rating Scale (HRS) (Strassman et al., 1994), the Altered States of Consciousness questionnaire (“Aussergewöhnliche Psychische Zustände”, APZ) (Dittrich, 1998), and the state version of the State-Trait Anxiety Inventory (STAI) (Spielberger, CD et al., 1970). Finally, self-administered Visual Analogue Scales (VAS) were used to retrospectively rate the following peak effects during the session: any effect, good effects, bad effects, sudden start of effects, fear, time, changes in dimensionality, changes in external reality, loss of contact with external reality, and visions. All questionnaires and VAS items were administered in Spanish.

Cardiovascular effects were captured by measuring systolic and diastolic blood pressure and heart rate while volunteers were in a recumbent position.

Neuroendocrine effects were captured by measuring cortisol, prolactin, growth hormone (GH), and salvinorin A (SA) pharmacokinetic parameters. The limits of quantification were 1 µg/dl for cortisol, 0.6 ng/ml for prolactin, 0.05 ng/ml for GH, and 0.035 mg/ml for SA.

Additional information on outcome measures is provided in the supplement.

Statistical analyses

The statistical analyses were conducted using the SPSS® software. Descriptive and inferential statistics were used on all measures. Scores on each questionnaire subscale and VAS item were calculated for each participant and dosing condition. Means and standard errors of the mean were used in the figures. Data were analyzed using repeated-measures ANOVAs with treatment as a repeated factor (placebo+placebo, placebo+salvinorin-A, antagonist+placebo, antagonist+salvinorin-A). When a significant effect of treatment was
found, post-hoc pair-wise comparisons between treatments were conducted using the Bonferroni correction as implemented in SPSS®.

For cardiovascular and neuroendocrine data, pre-administration (baseline) values were subtracted from post-administration measures. Subsequently, peak effect (maximum absolute change from baseline values) and area under the curve of effect versus time were calculated: from 0 to 120 min for cardiovascular measures (AUC0-120’); and from 0 to 240 min for hormone concentrations (AUC0-240’). The obtained values were analyzed using the aforementioned repeated-measures ANOVA followed by post-hoc comparisons between treatments using the Bonferroni correction.

Pharmacokinetic parameters were expressed for each group (group-1 and group-2) and pretreatment (placebo, naltrexone, ketanserin) as mean and standard deviations. To examine any possible pharmacokinetic interaction between salvinorin-A and the active pretreatments, pharmacokinetic parameters for salvinorin-A were compared in the absence and presence of the antagonists (naltrexone and ketanserin). Comparisons were conducted for each pharmacokinetic parameter using Student’s t-tests followed.

Results for the ANOVAs are given following Greenhouse-Geisser correction. Results were considered significant for p<0.05.
Results

All 24 participants completed the four experimental sessions and there were no drop-outs in the course of the study. Pharmacokinetic and neuroendocrine data from one volunteer in Group 1 (naltrexone) could not be obtained. This was due to malfunction of the intravenous catheter in the experimental session in which the participant received salvinorin-A alone.

Psychological effects

HRS

Mean scores on all subscales of the HRS for each group and treatment are shown in Figure 1. In Group 1 (naltrexone), significant effects of treatment were observed in all subscales of the HRS: Somaesthesia $F(3,33) = 24.68, p < 0.001$; Affect $F(3,33) = 21.25, p < 0.001$; Perception $F(3,33) = 22.39, p < 0.001$; Cognition $F(3,33) = 21.33, p < 0.001$; Volition $F(3,33) = 29.74, p < 0.001$; and Intensity $F(3,33) = 28.59, p < 0.001$. While salvinorin-A increased scores in all subscales, naltrexone effectively blocked these effects. Post-hoc comparisons using the Bonferroni correction showed significant naltrexone-induced reductions of the effects of salvinorin-A in all subscales: Somaesthesia $p < 0.01$; Affect $p < 0.001$; Perception $p < 0.01$; Cognition $p < 0.01$; Volition $p < 0.01$; and Intensity $p < 0.01$. Scores for the combination were not different from placebo (see Figure 1).

--------------------------

Insert Figure 1 about here

--------------------------
In Group 2 (ketanserin), a significant effect of treatment was again observed in all subscales: Somaesthesia $F(3,33) = 42.10$, $p < 0.001$; Affect $F(3,33) = 21.08$, $p < 0.001$; Perception $F(3,33) = 22.05$, $p < 0.001$; Cognition $F(3,33) = 30.26$, $p < 0.001$; Volition $F(3,33) = 16.99$, $p < 0.001$; and Intensity $F(3,33) = 110.74$, $p < 0.001$. Salvinorin-A increased scores on the HRS, and ketanserin co-administration did not modify this effect. The Post-hoc comparisons using the Bonferroni correction showed no significant variations in any subscale. To the contrary, scores for the combination were significantly different from placebo in all cases (see Figure 1).

APZ

Mean scores on all subscales of the APZ are shown in Figure 2. In Group 1 (naltrexone), significant effects of treatment were observed in the three subscales: OSE $F(3,33) = 18.40$, $p < 0.001$; AIA $F(3,33) = 10.72$, $p < 0.01$; VUS $F(3,33) = 28.61$, $p < 0.001$. Salvinorin-A led to significant increases in the scores of the three subscales. Naltrexone again blocked these effects. Post-hoc comparisons using the Bonferroni correction showed naltrexone-induced significant reductions: OSE $p < 0.01$; AIA $p < 0.05$; VUS $p < 0.001$.

In Group 2 (ketanserin), a significant effect of treatment was also observed in all subscales: OSE $F(3,33) = 34.75$, $p < 0.001$; AIA $F(3,33) = 10.71$, $p < 0.01$; VUS $F(3,33) = 19.34$, $p < 0.001$. Ketanserin had no effect when it was administered in combination with salvinorin-A. The Post-hoc comparisons using the Bonferroni correction showed no significant variations in any subscale. Scores for the combination remained significantly
different from placebo for the OSE and VUS subscales and showed a trend for AIA (see Figure 2).

State STAI

Mean scores on the state STAI are shown in Figure 3. In Group 1 (naltrexone), the ANOVA showed a main effect of treatment \( F(3,33) = 5.90, p < 0.05 \). Mean anxiety scores were highest after salvinorin-A. However, the post-hoc comparisons using the Bonferroni correction did not find differences with placebo for any treatment. Neither was the comparison between salvinorin-A alone and the salvinorin-A plus naltrexone combination.

\[ \text{--------------------------} \]

\text{Insert Figure 3 about here}

\[ \text{--------------------------} \]

In Group 2 (ketanserin), a significant effect of treatment was observed \( F(3,33) = 10.47, p < 0.01 \). In this sample, the salvinorin-induced increases in STAI mean values were marginally significant (\( p=0.051 \)). Ketanserin co-administration had no effect on the anxiogenic effects of salvinorin-A. On the contrary, scores for the combination showed less inter-subject variability and were significantly higher than placebo (see Figure 3).

VAS

Mean scores on all VAS items are shown in Figure 4. In Group 1 (naltrexone), significant effects of treatment were observed in all but one item: “any effect” \( F(3,33) = 67.11, p < 0.001 \); “good effects” \( F(3,33) = 10.78, p < 0.01 \); “sudden start of effects” \( F(3,33) = 81.23, p < 0.001 \); “fear” \( F(3,33) = 4.82, p < 0.05 \); “altered time perception” \( F(3,33) = 68.81,
p < 0.001; “altered body dimensionality” F(3,33) = 43.13, p < 0.001; “altered external reality” F(3,33) = 43.51, p < 0.001; “lost contact with external reality” F(3,33) = 124.88, p < 0.001; “visual effects” F(3,33) = 43.01, p < 0.001. The item “bad effects” only showed a trend F(3,33) = 4.44, p = 0.059. Salvinorin-A increased scores in all subscales, whereas naltrexone effectively blocked these effects. Post-hoc comparisons using the Bonferroni correction showed significant score reductions in the seven subscales showing the highest elevations after salvinorin: “any effect” p < 0.001; “sudden start of effects” p < 0.001; “altered time perception” p < 0.001; “altered body dimensionality” p < 0.001; “altered external reality” p < 0.001; “lost contact with external reality” p < 0.001; “visual effects” p < 0.001. Non-significant reductions were found for “good effects”, “bad effects” and “fear”, the scales showing the smallest effects when salvinorin-A was administered alone. Scores for the naltrexone+salvinorin-A combination on all subscales were not different from placebo (see Figure 4).

Insert Figure 4 about here

In Group 2 (ketanserin), a significant effect of treatment was observed in all VAS items: “any effect” F(3,33) = 133.98, p < 0.001; “good effects” F(3,33) = 20.04, p < 0.01; “bad effects” F(3,33) = 6.54, p < 0.001; “sudden start of effects” F(3,33) = 64.82, p < 0.001; “fear” F(3,33) = 7.37, p < 0.01; “altered time perception” F(3,33) = 27.18, p < 0.001; “altered body dimensionality” F(3,33) = 42.43, p < 0.001; “altered external reality” F(3,33) = 28.99, p < 0.001; “lost contact with external reality” F(3,33) = 31.98, p < 0.001; “visual effects” F(3,33) = 23.17, p < 0.001. Ketanserin administration had no effect on the salvinorin-induced increases. The Post-hoc comparisons using the Bonferroni correction found no significant
variations in any subscale. Scores for the combination were significantly different from placebo in all cases, except for “bad effects” and “fear” that showed only trends (see Figure 4).

Cardiovascular effects

The time course of cardiovascular measures is shown in Figure 5. In both groups, systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate (HR) values increased above the pre-administration baseline following salvinorin-A administration. This increase was very sharp and short-lived, peaking after the first measurement point and decreasing thereafter. The results of the statistical analyses are shown in Tables 1 and 2. SBP increases in peak values reached statistical significance in both groups, whereas DBP increases were only significant in Group 2. The brief nature of these increases is highlighted by the fact that the AUC values between 0-2h were not significantly different from placebo in either group. Neither were changes in HR peak and AUC after salvinorin-A.

Insert Figure 5 about here

In Group 1, naltrexone blocked the increases in SBP and DBP peak value, significantly reducing both values when it was administered together with salvinorin-A as compared when salvinorin-A was administered alone.

In Group 2, mean peak values after ketanserin+salvinorin-A were lower than those obtained after salvinorin-A alone. However, in contrast with the findings in group 1, these reductions were not statistically significant.
Neuroendocrine effects

The concentration-time curves for cortisol, growth hormone, and prolactin are shown in Figure 6 and the results of the statistical analyses in Tables 1 and 2. In Group 1, the intravenous catheter did not work properly and blood samples could not be obtained from one of the participants during experimental session in which salvinorin-A was administered alone. Thus, hormone levels could not be assessed for this participant and results are shown for only 11 volunteers.

In both groups, hormone levels increased above pre-administration values following salvinorin-A administration. However, statistical significance was only attained for cortisol and prolactin.

In Group 1, naltrexone reduced cortisol and prolactin levels when it was administered together with salvinorin-A as compared when salvinorin-A was administered alone. However, statistical significance was only attained for prolactin.

In Group 2, cortisol levels were lower for the ketanserin+salvinorin-A combination than for salvinorin-A alone. However, this reduction was not significant for peak values and only showed a trend for the AUC. In the case of prolactin, ketanserin did not inhibit its release. In fact, mean values were higher for the combination ketanserin+salvinorin-A than for salvinorin-A alone. However, these differences were not statistically significant.
Pharmacokinetics

The time course of salvinorin-A plasma concentrations and the calculated pharmacokinetic parameters are shown in Figure 7 and Table 3, respectively. As indicated above, blood samples could not be obtained from one of the participants in Group 1 when salvinorin-A was administered alone. Results are shown for 11 volunteers only.

As shown in the graphs and tables, drug levels were highest in the first and the second measurement points after the start of the inhalation. Values decreased rapidly thereafter, falling below 1 ng/ml at two hours after dosing. The statistical comparison of pharmacokinetic parameters in each group did not show any significant differences between the placebo+salvinorin and the antagonist+salvinorin sessions.
Discussion

Our results confirm the involvement of opioid receptors in the human pharmacology of salvinorin-A. The administration of naltrexone blocked the modified state of awareness induced by salvinorin-A in humans. On the contrary, pretreatment with the serotonin-2A antagonist ketanserin had no effect on the nature and intensity of the subjective experience.

The 1 mg dose of salvinorin-A and the route of administration chosen here induced a pattern of subjective effects of fast onset and short duration that replicated previous research conducted by our group in two different laboratories (Johnson et al., 2011; MacLean et al., 2013; Maqueda et al., 2015). The effects induced were reflected as significant increases in all three subscales of the APZ questionnaire, in the six subscales of the HRS and in an extensive battery of VAS items previously shown to be sensitive to salvinorin-A (Maqueda et al., 2015). The efficacy of vaporization followed by inhalation was further evidenced by the measurable levels of salvinorin-A found in plasma. The drug was rapidly absorbed reaching its maximum concentrations in the first two measurement time points at 1 and 2 minutes after dosing, in line with previous data in humans (Johnson et al., in press). This peak was followed by a rapid decrease. Assuming a parallel between plasma and CNS, these results suggest a rapid clearance from the brain, in line with observations in monkeys using nuclear medicine techniques (Hooker et al., 2008). This concentration-time pattern paralleled the time course of subjective effects described in previous studies using the same administration route (Johnson et al., 2011; MacLean et al., 2013; Maqueda et al., 2015).

The present findings support the involvement of the KOR in the subjective effects induced by salvinorin-A. The KOR and the dynorphins, its endogenous ligands, are broadly distributed throughout the central nervous system (Simonin et al., 1995). An agonist-mediated inhibitory effect of salvinorin-A on KOR-rich nuclei of the thalamus (Le Merrer et al., 2009) could explain the characteristic blockade of external audiovisual stimuli observed. On the
other hand, a study in rodents has shown that salvinorin-A increases fluorodeoxyglucose uptake in the sensory cortex (Hooker et al., 2009). Activation of neocortical areas of the temporal lobe could underlie the vivid visual imagery and auditory phenomena reported here. As hypothesized, naltrexone pretreatment blocked most aspects of the subjective experience (HRS, APZ, VAS, STAI), whereas ketanserin had no effect on any of these measures. Thus, salvinorin-A was shown to exert its effects on human perception, cognition, and emotion via opioidergic processes, without the involvement of serotonergic processes. Naltrexone is a nonspecific opioid receptor antagonist with the highest affinity for the mu and kappa receptors (μ:κ relative affinity of 1.7) and the lowest for the delta receptor (μ:δ relative affinity of 550) (Wentland et al., 2009). Naltrexone was administered at the 50 mg standard clinical dose. Doses of 25-30 mg had proved effective in previous studies to block the kappa-related effects of the opiates butorphanol and pentazocine (Preston and Bigelow, 1993; Walsh et al., 2008).

In addition to the thalamus and the neocortex, high KOR levels are also found in more primitive regions of the brain such as the hypothalamus, the ventral tegmental area and the nucleus accumbens (NAcc) (Simonin et al., 1995), associated with homeostasis, reward and motivation. In fact, besides its characteristic perceptual-cognitive effects, salvinorin-A also induced a series of cardiovascular and neuroendocrine effects when given alone. At the 1 mg dose, salvinorin-A consistently increased SBP, cortisol and prolactin levels in the two participant groups. While previous studies had not found effects of salvinorin-A on blood pressure and heart rate (Johnson et al., 2011; Addy, 2012; MacLean et al., 2013), increases in cortisol and prolactin had been reported (Johnson, MW et al., in press; Ranganathan et al., 2012). The absence of significant results on cardiovascular measures in the previous studies may be due to the small size of two of the studies (Johnson et al., 2011; MacLean et al., 2013), the length of time between measurements (Addy, 2012) and differences in the
vaporization method used which may have led to lower absorption and drug levels in plasma (Ranganathan et al., 2012).

The increased blood pressure and cortisol release observed could be a direct effect of salvinorin-A at the KOR sites. Synthetic KOR agonists increases cortisol in humans (Ur et al., 1997) and adrenocorticotropic and cortisol levels in monkeys (Pascoe et al., 2008). However, despite this evidence of a direct effect, an nonspecific stress reaction cannot be entirely ruled out, as these increases have also been reported for a broad range of psychoactive drugs with diverse mechanisms of action. They have been described for instance for the psychostimulant \textit{d}-amphetamine, which increases noradrenergic and dopaminergic neurotransmission, and for 5-HT$_{2A}$ agonist psychedelics such as ayahuasca (Dos Santos et al., 2011) and psilocybin (Hasler et al., 2004). Agonism at the KOR is able on its own to stimulate the hypothalamus (Hooker et al., 2009), potentially facilitating a direct drug effect on cortisol levels. Whereas KOR antagonists attenuate the physiological reactions to stress in rats (Fassini et al., 2015), agonists have been shown to induce large increases in vasopressin release in some but not all human subjects (Pfeiffer et al., 1986). This inter-subject variability in vasopressin response could provide another potential explanation for the disparity of results observed between laboratories regarding salvinorin-A effects on blood pressure.

Salvinorin-A administered alone increased prolactin plasma concentration, as previously reported for this drug (Johnson et al., in press) and other KOR agonists such as spiradoline (Ur et al., 1997). Prolactin release is physiologically under inhibitory control by dopaminergic neurotransmission, with amphetamine and other pro-dopaminergic drugs effectively blocking its release (Samuels et al., 2007; Dos Santos et al., 2011). The increase in prolactin concentrations induced by salvinorin-A could be secondary to the inhibition of dopamine release in the tuberoinfundibular pathway. KORs are localized on dopaminergic neurons where they exert a tonic inhibitory effects (Chefer et al., 2005). Several studies have
shown that kappa agonists decrease dopamine release in the NAcc (Spanagel et al., 1992; Maisonneuve et al., 1994), the ventral tegmental area (Margolis et al., 2003) and the prefrontal cortex (Heijna et al., 1990; Margolis et al., 2006). Additionally, repeated administration of kappa agonists leads to reductions in the levels of dopamine-2 receptors in the ventral striatum (Izenwasser et al., 1998). Animal research has shown that naltrexone administered alone reduces basal prolactin levels (Enjalbert et al., 1979), and here it effectively reduced prolactin release. By contrast, ketanserin pretreatment had no effect on this measure.

Mean GH plasma levels increased after salvinorin-A, but these were not statistically significant. In humans GH may be regulated by KOR, as levels increase following the administration of the synthetic KOR agonist spiradoline (Ur et al., 1997). Possibly the effect is not robust enough following salvinorin-A administration to be detected with the sample size used in the present study.

The global pattern of effects emerging from the present study is in accordance with animal studies that support the involvement of the KOR in salvinorin-A effects. Salvinorin-A induces hypolocomotion and antinociception effects that can be blocked by a selective KOR antagonist, but not by rimonabant (Walentiny et al., 2010). In rhesus monkeys, salvinorin-A stimulates prolactin release (Butelman et al., 2007), facial relaxation and ptosis (Butelman et al., 2009), as well as discriminative stimulus effects (Butelman et al., 2010). All these effects can be prevented by the KOR partial agonist nalmefene (Butelman et al., 2007, 2009) and the antagonist quadaazocine (Butelman et al., 2010). However, they cannot be blocked by ketanserin (Butelman et al., 2007, 2009, 2010) or rimonibant (Butelman et al., 2009).

To sum up, naltrexone but not ketanserin effectively blocked the subjective, cardiovascular and neuroendocrine effects of salvinorin-A in humans. The two pharmacological interaction studies conducted demonstrate the involvement of opioidergic,
rather than serotonergic neurotransmission in the effects of salvinorin-A in humans. These results are consistent with agonist actions of salvinorin-A at the kappa opioid receptor.
Funding

This work was supported by grant “PI12/02758” from the “Instituto de Salud Carlos III” of the Spanish Government, which is co-funded by FEDER. Marta Valle is supported by the “Fondo de Investigación Sanitaria” through grant CP04/00121 from the Spanish Ministry of Health in collaboration with Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau, Barcelona. Support for Dr. Griffiths was provided by NIDA Grant R01DA003889.
Acknowledgements

The authors would like to thank Laboratorio Echevarne for the neuroendocrine determinations and the study volunteers for their participation.
Conflict of interest

Dr. Griffiths’ research has been funded by NIH. He is member of the Board of Directors of the Heffter Research Institute, which also supports some of his research. Dr Griffiths and the rest of the authors declare no biomedical financial interests or potential conflicts of interest.
References


Dos Santos RG, Valle M, Bouso JC, Nomdedéu JF, Rodríguez-Espinosa J, Mcllhenney EH,


Johnson, MW, MacLean, KA, Caspers, MJ, Prisinzano, TE, Griffiths, RR (in press) Time course of pharmacokinetic and hormonal effects of inhaled high-dose salvinorin A in humans. J Psychopharmacol (Oxf).


Figure legends

**Figure 1:** Mean scores on the six Hallucinogen Rating Scale (HRS) subscales. Participants in Group 1 received placebo (green), 1 mg salvinorin-A (red), 50 mg naltrexone (yellow), and the combination naltrexone+salvinorin-A (blue). Participants in Group 2 received placebo (green), 1 mg salvinorin-A (red), 40 mg ketanserin (yellow), and the combination ketanserin+salvinorin-A (blue). Error bars denote 1 standard error of mean (n=12 in each group). Significant differences from placebo are denoted as * at p<0.05, ** at p<0.01, and *** at p<0.001. Significant differences between salvinorin-A alone and salvinorin-A after pretreatment with an antagonist (naltrexone or ketanserin) are denoted as † at p<0.05, †† at p<0.01, and ††† at p<0.001.

**Figure 2:** Mean scores on the Altered States of Consciousness (Aussergewöhnliche Psychische Zustände, APZ) questionnaire. Participants in Group 1 received placebo (green), 1 mg salvinorin-A (red), 50 mg naltrexone (yellow), and the combination naltrexone+salvinorin-A (blue). Participants in Group 2 received placebo (green), 1 mg salvinorin-A (red), 40 mg ketanserin (yellow), and the combination ketanserin+salvinorin-A (blue). Error bars denote 1 standard error of mean (n=12 in each group). Significant differences from placebo are denoted as * at p<0.05, ** at p<0.01, and *** at p<0.001. Significant differences between salvinorin-A alone and salvinorin-A after pretreatment with an antagonist (naltrexone or ketanserin) are denoted as † at p<0.05, †† at p<0.01, and ††† at p<0.001.
Figure 3: Mean scores on the state STAI questionnaire. Participants in Group 1 received placebo (green), 1 mg salvinorin-A (red), 50 mg naltrexone (yellow), and the combination naltrexone+salvinorin-A (blue). Participants in Group 2 received placebo (green), 1 mg salvinorin-A (red), 40 mg ketanserin (yellow), and the combination ketanserin+salvinorin-A (blue). Error bars denote 1 standard error of mean (n=12 in each group). Significant differences from placebo are denoted as * at p<0.05, ** at p<0.01, and *** at p<0.001. Significant differences between salvinorin-A alone and salvinorin-A after pretreatment with an antagonist (naltrexone or ketanserin) are denoted as † at p<0.05, †† at p<0.01, and ††† at p<0.001.

Figure 4: Mean scores on the self-administered visual analogue scales (VAS) items. Participants in Group 1 received placebo (green), 1 mg salvinorin-A (red), 50 mg naltrexone (yellow), and the combination naltrexone+salvinorin-A (blue). Participants in Group 2 received placebo (green), 1 mg salvinorin-A (red), 40 mg ketanserin (yellow), and the combination ketanserin+salvinorin-A (blue). Error bars denote 1 standard error of mean (n=12 in each group). Significant differences from placebo are denoted as * at p<0.05, ** at p<0.01, and *** at p<0.001. Significant differences between salvinorin-A alone and salvinorin-A after pretreatment with an antagonist (naltrexone or ketanserin) are denoted as † at p<0.05, †† at p<0.01, and ††† at p<0.001.

Figure 5: Time course of cardiovascular measures. Panels on the left show mean data for systolic blood pressure, diastolic blood pressure and heart rate for Group 1 (naltrexone, n=12). Panels on the right show mean data for systolic blood pressure, diastolic blood pressure and heart rate for Group 2 (ketanserin, n=12). The plots show data following placebo+placebo
(circle), antagonist (naltrexone or ketanserin)+placebo (square), placebo+salvinorin (triangle), and antagonist+salvinorin (diamond). Error bars denote ±1 standard error of mean.

Figure 6: Time course of neuroendocrine measures. Panels on the left show mean data for cortisol, growth hormone and prolactin for Group 1 (naltrexone, n=11). Panels on the right show mean data for cortisol, growth hormone and prolactin for Group 2 (ketanserin, n=12). The plots show data following placebo+placebo (circle), antagonist (naltrexone or ketanserin)+placebo (square), placebo+salvinorin (triangle), and antagonist+salvinorin (diamond). Error bars denote ±1 standard error of mean.

Figure 7: Time course of salvinorin-A concentrations. The left panel shows mean data for Group 1 (salvinorin-A and salvinorin-A+naltrexone, n=11). The right panel shows mean data for Group 2 (salvinorin-A and salvinorin-A+ketanserin, n=12).
Table 1: Cardiovascular and hormone data from Group-1. Effects induced by placebo (placebo+placebo), salvinorin-A (placebo+salvinorin-A), naltrexone (naltrexone+placebo) and naltrexone+salvinorin-A on cardiovascular and neuroendocrine measures. Means (SD) of values obtained (n=12 for cardiovascular measures and n=11 for hormones), and results of the statistical analyses performed. The comparison naltrexone vs naltrexone+salvinorin-A has been omitted.

<table>
<thead>
<tr>
<th></th>
<th>PL</th>
<th>SA</th>
<th>NA</th>
<th>NASA</th>
<th>F(3,33)</th>
<th>p</th>
<th>Pairwise comparisons (Bonferroni)*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cardiovascular</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SBP _pk (mmHg)</td>
<td>-1.17 (6.19)</td>
<td>17.08 (14.41)</td>
<td>-4.25 (7.34)</td>
<td>-0.50 (8.24)</td>
<td>15.10</td>
<td>&lt;0.001</td>
<td>0.006 NS NS 0.003 0.001</td>
</tr>
<tr>
<td>SBP _AUC (mmHg·min)</td>
<td>-123.75 (365.36)</td>
<td>133.54 (308.24)</td>
<td>-270.83 (406.70)</td>
<td>-147.08 (335.64)</td>
<td>2.69</td>
<td>0.096 NS NS NS NS NS</td>
<td></td>
</tr>
<tr>
<td>DBP _pk (mmHg)</td>
<td>0.33 (3.50)</td>
<td>8.08 (9.06)</td>
<td>-3.42 (3.96)</td>
<td>0.00 (5.34)</td>
<td>8.64</td>
<td>0.002 NS NS NS 0.019 0.016</td>
<td></td>
</tr>
<tr>
<td>DBP _AUC (mmHg·min)</td>
<td>-67.92 (256.38)</td>
<td>142.08 (217.08)</td>
<td>-211.88 (234.13)</td>
<td>-186.67 (304.83)</td>
<td>4.48</td>
<td>0.020 NS NS NS 0.030 0.036</td>
<td></td>
</tr>
<tr>
<td>HR _pk (bpm)</td>
<td>-2.42 (6.84)</td>
<td>11.08 (13.59)</td>
<td>-4.42 (5.90)</td>
<td>1.08 (4.27)</td>
<td>6.97</td>
<td>0.009 NS NS NS 0.047 NS</td>
<td></td>
</tr>
<tr>
<td>HR _AUC (bpm·min)</td>
<td>-159.79 (470.13)</td>
<td>53.75 (275.17)</td>
<td>-272.29 (418.65)</td>
<td>-125.63 (211.35)</td>
<td>1.68</td>
<td>0.205 NS NS NS NS NS</td>
<td></td>
</tr>
<tr>
<td><strong>Hormones</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>F(3,30)</td>
<td>p</td>
<td></td>
</tr>
<tr>
<td>Cort _pk (µg/dL)</td>
<td>-0.65 (3.01)</td>
<td>8.73 (2.29)</td>
<td>1.65 (7.05)</td>
<td>5.25 (3.36)</td>
<td>9.02</td>
<td>0.002 &lt;0.001 NS 0.023 0.037 NS</td>
<td></td>
</tr>
<tr>
<td>Cort _AUC (µg/dL·min)</td>
<td>-66.4 (419.4)</td>
<td>539.1 (405.9)</td>
<td>4.48 (774.7)</td>
<td>324.6 (540.9)</td>
<td>3.02</td>
<td>0.075 0.012 NS NS NS NS</td>
<td></td>
</tr>
<tr>
<td>GH _pk (ng/mL)</td>
<td>2.96 (3.49)</td>
<td>7.62 (7.51)</td>
<td>2.88 (3.00)</td>
<td>6.81 (6.48)</td>
<td>2.88</td>
<td>0.082 NS NS NS 0.081 NS NS</td>
<td></td>
</tr>
<tr>
<td>GH _AUC (ng/mL·min)</td>
<td>221.6 (231.7)</td>
<td>513.7 (521.4)</td>
<td>207.5 (243.8)</td>
<td>569.5 (520.2)</td>
<td>2.75</td>
<td>0.093 NS NS NS 0.040 NS NS</td>
<td></td>
</tr>
<tr>
<td>Prol _pk (ng/mL)</td>
<td>3.55 (2.22)</td>
<td>27.09 (19.84)</td>
<td>3.49 (5.54)</td>
<td>7.24 (12.61)</td>
<td>12.63</td>
<td>0.001 0.05 NS NS 0.021 0.003</td>
<td></td>
</tr>
<tr>
<td>Prol _AUC (ng/mL·min)</td>
<td>192.7 (314.4)</td>
<td>1848.6 (1169.0)</td>
<td>142.9 (585.6)</td>
<td>390.3 (892.1)</td>
<td>14.74</td>
<td>&lt;0.001 0.03 NS NS 0.011 0.007</td>
<td></td>
</tr>
</tbody>
</table>

PL: placebo+placebo, SA: placebo+salvinorin-A, NA: naltrexone+placebo, NASA: naltrexone+salvinorin-A; pk: peak value; AUC: area under the curve; SBP: systolic blood pressure; DBP: diastolic blood pressure, HR: heart rate: Cort: cortisol; GH: growth hormone; Prol: prolactin; *(a)* p values.
Table 2: Cardiovascular and hormone data from Group-2. Effects induced by placebo (placebo+placebo), salvinorin-A (placebo+salvinorin-A), ketanserin (ketanserin+placebo) and ketanserin+salvinorin-A on cardiovascular and neuroendocrine measures. Means (SD) of values obtained (n=12), and results of the statistical analyses performed. The comparison ketanserin vs ketanserin+salvinorin-A has been omitted.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cardiovascular</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SBP_pk (mmHg)</td>
<td>-2.50 (5.00)</td>
<td>12.00 (10.14)</td>
<td>-0.75 (3.82)</td>
<td>6.92 (13.38)</td>
<td>8.13</td>
<td>0.003</td>
<td>0.013</td>
<td>NS</td>
<td>NS</td>
<td>0.011</td>
<td>NS</td>
</tr>
<tr>
<td>SBP_AUC (mmHg·min)</td>
<td>-236.88 (288.58)</td>
<td>222.92 (504.39)</td>
<td>-98.75 (259.67)</td>
<td>-281.88 (496.15)</td>
<td>4.59</td>
<td>0.012</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>0.070</td>
</tr>
<tr>
<td>DBP_pk (mmHg)</td>
<td>-2.00 (4.20)</td>
<td>9.00 (7.48)</td>
<td>-5.00 (7.19)</td>
<td>1.67 (8.49)</td>
<td>12.25</td>
<td>&lt;0.001</td>
<td>0.004</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>0.001</td>
</tr>
<tr>
<td>DBP_AUC (mmHg·min)</td>
<td>-247.71 (266.43)</td>
<td>153.75 (280.70)</td>
<td>-277.08 (357.59)</td>
<td>-165.83 (281.18)</td>
<td>5.58</td>
<td>0.007</td>
<td>0.058</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>0.008</td>
</tr>
<tr>
<td>HR_pk (bpm)</td>
<td>-0.75 (5.99)</td>
<td>6.75 (10.01)</td>
<td>-0.92 (4.62)</td>
<td>2.83 (10.88)</td>
<td>2.71</td>
<td>0.083</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>HR_AUC (bpm·min)</td>
<td>-162.08 (277.20)</td>
<td>-31.67 (268.53)</td>
<td>-223.33 (383.41)</td>
<td>-371.88 (437.46)</td>
<td>2.03</td>
<td>0.144</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td><strong>Hormones</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cort_pk (µg/dL)</td>
<td>-0.66 (5.62)</td>
<td>6.06 (7.44)</td>
<td>-3.74 (5.61)</td>
<td>4.75 (6.43)</td>
<td>7.44</td>
<td>0.004</td>
<td>0.009</td>
<td>NS</td>
<td>0.081</td>
<td>0.083</td>
<td>NS</td>
</tr>
<tr>
<td>Cort_AUC (µg/dL·min)</td>
<td>-269.1 (600.9)</td>
<td>425.0 (691.3)</td>
<td>-750.0 (569.8)</td>
<td>83.7 (562.5)</td>
<td>11.98</td>
<td>0.001</td>
<td>0.005</td>
<td>NS</td>
<td>NS</td>
<td>0.013</td>
<td>0.078</td>
</tr>
<tr>
<td>GH_pk (ng/mL)</td>
<td>1.60 (1.66)</td>
<td>4.71 (3.80)</td>
<td>1.83 (2.77)</td>
<td>3.67 (3.23)</td>
<td>3.55</td>
<td>0.032</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>GH_AUC (ng/mL·min)</td>
<td>162.2 (213.2)</td>
<td>304.9 (278.4)</td>
<td>135.4 (184.7)</td>
<td>206.9 (225.3)</td>
<td>1.51</td>
<td>0.233</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Prol_pk (ng/mL)</td>
<td>0.78 (4.45)</td>
<td>20.78 (14.81)</td>
<td>1.48 (5.69)</td>
<td>28.18 (18.10)</td>
<td>20.79</td>
<td>&lt;0.001</td>
<td>0.007</td>
<td>NS</td>
<td>0.002</td>
<td>0.012</td>
<td>NS</td>
</tr>
<tr>
<td>Prol_AUC (ng/mL·min)</td>
<td>-26.2 (547.5)</td>
<td>1231.1 (903.8)</td>
<td>182.8 (776.4)</td>
<td>1698.9 (1216.4)</td>
<td>18.48</td>
<td>&lt;0.001</td>
<td>0.002</td>
<td>NS</td>
<td>0.001</td>
<td>0.034</td>
<td>NS</td>
</tr>
</tbody>
</table>

PL: placebo+placebo, SA: placebo+salvinorin-A, KET: ketanserin+placebo, KETSA: ketanserin+salvinorin-A; pk: peak value; AUC: area under the curve; SBP: systolic blood pressure; DBP: diastolic blood pressure, HR: heart rate; Cort: cortisol; GH: growth hormone; Prol: prolactin. (a) p values.
Table 3: Pharmacokinetic parameters for salvinorin-A for each group (Group-1 and Group-2) and experimental session in which it was administered (placebo+salvinorin-A and antagonist+salvinorin-A). Values indicate mean (SD). In Group-1, values were calculated for 11 volunteers only. Pairwise comparisons were conducted using within-subjects Student’s t-tests.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Group-1 (n=11)</th>
<th>Group-2 (n=12)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>placebo + salvinorin-A</td>
<td>naltrexone + Salvinorin-A</td>
</tr>
<tr>
<td>$T_{max}$ (min)</td>
<td>1.36 (0.50)</td>
<td>1.36 (0.50)</td>
</tr>
<tr>
<td>$C_{max}$ (ng/ml)</td>
<td>31.28 (13.38)</td>
<td>40.34 (36.95)</td>
</tr>
<tr>
<td>$AUC_{0-240}$ (ng/ml · min)</td>
<td>463.61 (132.77)</td>
<td>436.76 (106.58)</td>
</tr>
<tr>
<td>$AUC_{0-\infty}$ (ng/ml · min)</td>
<td>487.36 (142.24)</td>
<td>457.06 (113.82)</td>
</tr>
<tr>
<td>$t_{1/2z}$ (min)</td>
<td>50.44 (14.79)</td>
<td>56.96 (7.77)</td>
</tr>
<tr>
<td>$Cl/F$(l/min)</td>
<td>2.33 (1.17)</td>
<td>2.32 (0.62)</td>
</tr>
<tr>
<td>$V_z/F$ (l)</td>
<td>166.32 (77.47)</td>
<td>188.80 (46.00)</td>
</tr>
</tbody>
</table>

Group-2 (n=12)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>placebo + salvinorin-A</th>
<th>ketanserin + Salvinorin-A</th>
<th>t(11)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>$T_{max}$ (min)</td>
<td>1.50 (0.52)</td>
<td>1.42 (0.51)</td>
<td>0.432</td>
<td>NS</td>
</tr>
<tr>
<td>$C_{max}$ (ng/ml)</td>
<td>31.25 (15.4)</td>
<td>50.04 (37.64)</td>
<td>-1.89</td>
<td>NS</td>
</tr>
<tr>
<td>$AUC_{0-240}$ (ng/ml · min)</td>
<td>358.29 (162.69)</td>
<td>423.82 (215.71)</td>
<td>-0.90</td>
<td>NS</td>
</tr>
<tr>
<td>$AUC_{0-\infty}$ (ng/ml · min)</td>
<td>371.14 (168.91)</td>
<td>440.40 (219.39)</td>
<td>0.93</td>
<td>NS</td>
</tr>
<tr>
<td>$t_{1/2z}$ (min)</td>
<td>49.21 (15.58)</td>
<td>56.24 (16.80)</td>
<td>-1.28</td>
<td>NS</td>
</tr>
<tr>
<td>$Cl/F$(l/min)</td>
<td>3.32 (1.60)</td>
<td>2.83 (1.51)</td>
<td>0.95</td>
<td>NS</td>
</tr>
<tr>
<td>$V_z/F$ (l)</td>
<td>237.08 (133.90)</td>
<td>223.00 (100.75)</td>
<td>0.41</td>
<td>NS</td>
</tr>
</tbody>
</table>
Figure 3

State-Trait Anxiety Inventory (STAI)

![Bar chart showing mean scores for two groups: Group 1: Naltrexone and Group 2: Ketanserin. The chart includes error bars and symbols for statistical significance.](image)
Figure 5